Skip to main content

Table 4 Predictors for treatment related long-term side effects

From: Employment status and health related quality of life among Hodgkin-lymphoma survivors’– results based on data from a major treatment center in Hungary

  Treatment related long- term side effects No treatment related long-term side effects P
Gender
 Male (n = 69) 28 (41%) 41 (59%) 0.011
 Female (n = 71) 44 (62%) 27 (38%)
Chemotherapy
 A(E)BVD (n = 95) 38 (40%) 57 (60%) <0.001
 Other than ABVD (n = 43) 33 (77%) 10 (23%)
  1. A(E)BVD: adriamycin, (epirubicin), bleomycin, vinblastine and dacarbazine; Other than ABVD: CV(O)PP:cyclophosphamide, vinblastine [vincristine], procarbazine and prednisolone; COPP/ABV:cyclophosphamide, vincristine, procarbazine, prednisolone/adriamycin, bleomycin and vinblastine